PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, today announced that it had signed new distribution agreements for RenalGuard® with Girlow USA, LLC, Cenas, Co., Ltd, and Pyramed Ltd., following its successful participation in EuroPCR in France earlier this month.
Under terms of these agreements, PLC will expand its ability to distribute its innovative RenalGuard System™ to Mexico and several countries in Central America and South America, as well as Turkey and the United Kingdom, and initial stocking orders of RenalGuard consoles and single use sets have been purchased.
RenalGuard is CE-marked and can be sold immediately in the United Kingdom. Cenas has applied for Ministry of Health approval to market the product in Turkey.
Girlow USA is registering RenalGuard for sale in Mexico and on a country by country basis in Central America and South America.
“These new distributors will enable PLC to expand the use of RenalGuard more deeply in important markets in Europe, and to continue our penetration of the growing healthcare markets in Mexico, Central America and South America,” said Mark R. Tauscher, President and Chief Executive Officer of PLC Systems.
“Our new partners are successful distributors in their respective markets and we believe their addition to our worldwide distributor network will help in our efforts to increase worldwide adoption of RenalGuard.”
These agreements expand RenalGuard’s distribution footprint into three new markets, complementing its existing presence in Europe, Israel, and Brazil and in select other countries around the world. PLC’s U.S. pivotal trial of RenalGuard, which is required to secure approval from the U.S. Food & Drug Administration to market and sell RenalGuard in the U.S., began in late 2011.